Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — Non-Deal Roadshow (November 2020)
79 slides from Coloplast A/s Class B's roadshow presentation, November 2020
Slide 1: Sustainable growth leadership
Sustainable growth leadership Leading intimate healthcare Roadshow presentation FY 2019/20 Making life easier Ostomy Care, Continence Care, Wound & Skin Care and Interventional Urology
Slide 2: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 3: Back to organic growth in Q4. Solid results for FY 2019/20
Back to organic growth in Q4. Solid results for FY 2019/20 despite challenging year due to COVID-19 pandemic 2019/20 Highlights Revenue growth +4% • Organic growth of 4% and 3% reported growth in DKK Reported revenue (DKKm) • FY organic growth negatively impacted by COVID-19, particularly the +3% ca
Slide 4: Coloplast acquires Nine Continents Medical Inc
Coloplast acquires Nine Continents Medical Inc, an early stage company in the large over-active bladder segment Over-active bladder market Company and product description • Over-active bladder (OAB) is a condition that causes a frequent and • Nine Continents Medical Inc is an early stage company pio
Slide 5: All business areas adversely impacted by COVID-19 in 2019/20
All business areas adversely impacted by COVID-19 in 2019/20 in particular Interventional Urology FY 19/20 revenue by business area FY 19/20 revenue by geography Business Reported revenue Organic growth Geographic Reported revenue Organic growth Share of organic area DKKm area DKKm growth Ostomy Car
Slide 6: Ostomy Care grew 6% organically in FY 2019/20
Ostomy Care grew 6% organically in FY 2019/20, adversely impacted by lower growth in new patients in Europe Ostomy Care performance Comments • Full year organic growth of 6% (reported growth 5%). Q4 organic growth of 3% (reported growth 0%) 10 10 • In Q4, growth was driven by China and the US but ne
Slide 7: Continence Care performance
Ostomy Care grew 6% organically in 2019/20, adversely impacted by lower growth in new patients across Europe Continence Care performance Comments 12 • FY 2019/20 organic growth of 6% (reported growth 6%). Q4 organic growth of 4% (reported growth 2%) • In Q4, growth was driven by the US, Argentina, G
Slide 8: Interventional Urology declined 7% organically in 2019/20
Interventional Urology declined 7% organically in 2019/20 due to COVID-19, but almost returned to growth in Q4 Interventional Urology performance Comments • FY 2019/20 negative organic growth of -7% (-7% reported growth). Q4 flat organic growth (-3% reported growth) 14 11 12 • Similar to Q3 but to a
Slide 9: Wound Care delivered 1% organic growth in 2019/20
Wound Care delivered 1% organic growth in 2019/20 due to low hospital activity in particular in China due to COVID-19 Wound & Skin Care performance Comments 11 • FY 2019/20 organic growth of 1% in Wound & Skin Care (0% reported 10 growth). Q4 negative organic growth of -3% in Wound & Skin Care (-6%
Slide 10: FY 2019/20 revenue growth adversely impacted by COVID-19
FY 2019/20 revenue growth adversely impacted by COVID- 19 and depreciation of emerging market currencies Comments Revenue development • FY 2019/20 reported revenue increased by DKK 605m (DKKm) or 3% compared to FY 2018/19 737 • The majority of growth was driven by organic growth 18,544 contributing
Slide 11: EBIT margin of 32% in 2019/20
EBIT margin of 32% in 2019/20 driven by prudent cost management and lower travel & marketing spend Comments EBIT margin development (%) • FY 19/20 gross margin of 68% in DKK on par with last year 0.1 0.0 -0.2 • Positive impact from GOP4 and the closure of the Thisted factory in 0.4 June 2019 31.6 •
Slide 12: FCF driven by solid underlying development in earnings
FCF driven by solid underlying development in earnings FCF development Comments • Free cash flow in FY 2019/20 was DKK 3,858m, up 2% compared to DKK 3,766 in FY 2018/19 not adjusting for mesh payments 98 99 98 • Adjusted for the positive impact of DKK 197m related to the 92 93 90 reclassification of
Slide 13: Financial guidance for FY 2020/21
Financial guidance for FY 2020/21 Guidance 2020/21 Guidance 2020/21 (DKK)* Key assumptions • Phasing of growth expected to be back-end loaded with low single-digit growth in H1 and double-digit growth in H2 7-8% • Interventional Urology positively impacted by comparison period in 2019/20 Sales growt
Slide 14: Introduction to Coloplast
Making it easier to be yourself Leading intimate healthcare Introduction to Coloplast Stina Making life easier Ostomy Care, Continence Care, Wound & Skin Care and Interventional Urology
Slide 15: Coloplast has four business areas all with global sales presence
Coloplast has four business areas all with global sales presence Group revenue 2019/20 by segment Group revenue 2019/20 by geography X = Coloplast’s global market position Emerging markets 17% Ostomy Care Continence 40% Care 37% #1 DKK DKK 18.5bn #1 18.5bn Other European developed markets markets 58
Slide 16: Coloplast specializes in intimate healthcare needs
Coloplast specializes in intimate healthcare needs Who are our typical users How do we help them? People who have had their intestine redirected to an SenSura® Mio opening in the abdominal wall Ostomy bag Ostomy Care People in need of bladder or bowel management SpeediCath® Continence Flexible male
Slide 17: The Chronic Care model secures a predictable revenue stream
The Chronic Care model secures a predictable revenue stream and stable revenue growth The chronic care user flow Chronic Care condition New user Installed base of users Stable flow of loyal users Solid reimbursement Coloplast group revenues Revenue (DKKbn) Organic growth (%) 10 10 9 8 8 8 8 7 7 7 7
Slide 18: Intimate healthcare is characterized by stable industry trends
Intimate healthcare is characterized by stable industry trends Drivers Limiters Earlier detection and Growing elderly Surgical and cure, eventually 1 Demographics population increases 1 medical trends reduces addressable customer base for market for Coloplast Coloplast products treatment products Ex
Slide 19: Strong market positions in Europe and potential outside Europe
Coloplast has strong market positions in Europe and great commercial potential outside Europe Europe Developed Emerging Ostomy Continence Urology Wound Care Addressable market 18-19n 14-15bn 11-12bn 22-24bn 4-5% 5-6% 3-5% 2-4% Size in DKK Growth in % Coloplast 40 - 50% 45 - 55% 20 - 25% 5 - 10% regi
Slide 20: We are building the consumer healthcare company of the future
We are building the consumer healthcare company of the future Chronic Care Macro Trends Impact Commercial model Ageing population Superior, clinically differentiated products Healthcare consumerism Digital transformation Consumer preference Data and Clinical digital tools preference Price pressure P
Slide 21: Our new strategy will drive continued long-term value creation
Our new strategy will drive continued long-term value creation through revenue and earnings growth Chronic Care Interventional Wound & Urology Skin Care 7-9% more than30% organic growth p.a. EBIT margin1 Talent, Innovation Leadership & Culture Unparalleled Sustainability efficiency 1) Constant curre
Slide 22: Supporting sustainable development
Supporting sustainable development with a strong emphasis on improving our environmental performance Our mission Making life easier for people with intimate healthcare needs Our 2025 priority Our 2025 priority Reducing Improving emissions products and packaging 0 emissions from scope 1&2 80% packagi
Slide 23: Yearly incremental investments of up to 2% of revenue
We will continue to support organic growth by yearly incremental investments of up to 2% of revenue Key Investment Decision Drivers Key Investment Areas ✓ We expect to invest up to 2% Economics & of revenue in incremental OPEX investments Government ✓ Innovation Market Attractiveness Chronic Care ✓
Slide 24: We will actively pursue M&A opportunities
We will actively pursue M&A opportunities as a lever for long-term growth Opportunity based Systematic screening Channel Portfolio expansion Early stage Large plays expansion & adjacencies technologies Page 24
Slide 25: Key enablers to support the commercial model in Chronic Care
We have built key enablers to support the commercial model in our Chronic Care businesses Commercial model Key enablers Direct Businesses Superior, clinically differentiated products Coloplast Consumer Care Consumer Clinical preference Data and digital tools preference Direct to Consumer Data & Digi
Slide 26: Direct business in Chronic Care serving consumers
Direct business in Chronic Care serving consumers drives improved outcomes and is a vital component of our growth Direct presence in top 5 markets and strategic rationale Coloplast Care presence 1 Control and continuity of product supply ~30% MS ~10% MS ~5% MS +30 countries 2 Target the full value p
Slide 27: Clinical Performance Program to tackle the biggest issues users face
We have initiated a very ambitious Clinical Performance Program to tackle the biggest issues users face What really matters to people using catheters? What really matters to people living with a stoma? 45 %* of users describe UTIs are their 93 % worry about leakage2 greatest challenge in life1 * Peo
Slide 28: Progress across the Clinical Performance Program
We have made significant progress across the Clinical Performance Program Progress as of today Strive25 strategy period ends in 2025 Additional pilot study to further test the Product launch Digital ostomy technology in broader setup expected in first solution Pilot studies conducted with successful
Slide 29: Profitability supported by scalability and efficiency gains
Profitability supported by scalability and efficiency gains enabling additional investments within distribution and R&D Gross margin development, in % of revenue Cost item Development, in % of revenue 0.6%-points 28.1 28.1 28.7 29.0 28.7 28-30 Distribution - 0.3%-points 68.3 68.1 67.3 67.7 68.0 0.3%
Slide 30: Automation, procurement and scale in Global Operations
Automation, procurement and scale are key to bringing Global Operations to the next level 1. Automation to mitigate growth in blue-collar FTE >1,000 DKK ~450m 10% ~800 CAPEX investment over # of FTE release ~500 through automation ~200 four years (19/20 – 22/23) Salary1 19/20 20/21 21/22 22/23 (Dire
Slide 31: Global Business Support and IT landscape
A global Business Support and IT landscape enables Coloplast to scale faster and more efficiently Global Business Services Global business services handle the majority of all global support % of group processes 100% ~90% 100% IT infrastructure Finance/ Master Data Global Business & support accountin
Slide 32: EBIT margin development drivers
EBIT margin development continues to be a function of growth, scalability, cost discipline and investment activity EBIT margin (%) Future drivers of EBIT margin ILLUSTRATIVE EBIT will be positively impacted by: + Leverage effect on fixed costs e.g. >30% distribution, admin and R&D costs ~31% especia
Slide 33: Free cash flow during the Strive25 strategy period
Continued strong development in free cash flow during the Strive25 strategy period Taxation Net working capital CAPEX(2) Reported tax rate Net working capital in % revenue Depreciation in % of revenue CAPEX DKKm CAPEX in % of revenue 5% 6% 4% 4% 4% 4% 5% 4% 4% 4% 4% 4% 24% ~24% 931 23% 23% 23% 23% 2
Slide 34: Attractive cash returns despite large investments
We will continue to provide attractive cash returns despite large investments in commercial and expansion activities Coloplast cash distribution to investors Comments • Coloplast returns excess liquidity to Dividends paid out in the year (mDKK) (1) Share buy-back (DKKm) Pay-out ratio (%) (2) shareho
Slide 35: In sum, stable shareholder returns through ...
In sum, we believe Coloplast can continue to deliver stable shareholder returns through ... 32% Comments • Stable market trends in our Chronic Care business • Strong Coloplast Care retention program and innovative DtC 10% activities 9% 4% • Increased focus on growing the business outside Europe • Ad
Slide 36: Appendices
Leading intimate healthcare Appendices
Slide 37: The Coloplast share (COLO-B.CO)
The Coloplast share (COLO-B.CO) Share Capital Ownership Coloplast share listed on Nasdaq Copenhagen since 1983 ~200 billion DKK (~33 billion USD) market cap @ ~931 DKK per 11% share (incl. A shares) 4% 2% Two share classes: 46% • 18m A shares carry 10 votes (family) • 198m B shares carry 1 vote (fre
Slide 38: Capital structure
Capital structure Comments Net interest bearing debt • Overall policy is that excess liquidity is returned to shareholders through a 0.1x 0.1x 0.1x 0.2x combination of dividends and share buy- backs -0.2x • Interest bearing debt will be raised in connection with a major acquisition or other special
Slide 39: Q4 returned to growth but all areas still negatively impacted
Q4 returned to growth but all business areas and regions are still negatively impacted by COVID-19 Q4 19/20 revenue by business area Q4 19/20 revenue by geography Business Reported revenue Organic growth Geographic Reported revenue Organic growth Share of organic area DKKm area DKKm growth Ostomy Ca
Slide 40: Q4 2019/20 reported revenue declined -1%
Q4 2019/20 reported revenue declined -1% due to significant depreciation in USD and Emerging market currencies Comments Revenue development • Q4 2019/20 reported revenue decline by DKK 28m or (DKKm) -1% compared to Q4 2018/19 104 • Q4 organic growth of 2% or DKK 104m • Drivers related to the COVID-1
Slide 41: EBIT in Q4 was on par with last year
EBIT in Q4 was on par with last year due to lower revenues but continued prudent cost control Comments EBIT margin development (%) • Q4 gross margin of 69% in DKK compared to 69% last year 0.1 -0.2 • Positive impact from savings from the Global Operations Plan 4 0.2 • Negative impact from product mi
Slide 42: Key Value Ratios
Key Value Ratios Profitability drivers Free Cash Flow drivers 31.9 32.7 32.3 36.6 36.3 36.2 31.7 32.0 34.7 34.6 28.1 28.7 29.0 28.1 28.7 25.2 23.8 23.4 23.6 23.4 3.8 4.0 4.0 4.2 4.1 5.0 4.4 4.4 4.1 3.5 3.5 3.7 3.9 3.9 3.8 15/16 16/17 17/18 18/19 19/20 15/16 16/17 17/18 18/19 19/20 Admin-to-Sales (%)
Slide 43: Revenue development by business area
Coloplast revenue development by business area Ostomy Care Interventional Urology 9 7,538 13 7,166 6,291 6,643 10 10 10 5,935 8 9 10 6 10 8 6 9 9 6 1,641 1,740 1,970 1,835 7 7 1,497 7 67 5 5 6 -7 15/16 16/17 17/18 18/19 19/20 15/16 16/17 17/18 18/19 19/20 Continence Care Wound & Skin Care 6,459 6,81
Slide 44: Revenue development by geography and total
Coloplast revenue development by geography and total Europe Other Developed Markets 10,573 10,820 9,213 9,394 9,941 15 16 8 11 8 11 6 6 5 6 6 3,791 4,380 4,644 3,177 3,642 2 4 2 5 6 6 4 5 15/16 16/17 17/18 18/19 19/20 15/16 16/17(1) 17/18 18/19 19/20 Emerging Markets Coloplast group 17,939 18,544 15
Slide 45: Segment operating profit
Segment operating profit (Excludes shared/non-allocated costs) Chronic Care Interventional Urology Wound & Skin Care Ostomy and Continence Care 60 59 59 41 40 39 40 41 40 57 57 37 2,083 2,168 2,092 34 35 2,047 2,011 197 199 170 179 250 248 238 25 225 230 79 Q4 18/19 Q1 19/20 Q2 19/20 Q3 19/20 Q4 19/
Slide 46: Exchange rate exposure FY 2020/21 and hedging policy
Exchange rate exposure FY 2020/21 and hedging policy Revenue FX exposure 2020/21(1) 12 months exposure from 10% initial exchange rate drop(1) Other 17% -410 USD -170 EUR 36% -280 CNY, JPY, AUD, BRL & ARS 13% GBP -190 HUF 0 100 14% GBP 20% Revenue (DKKm) EBIT (DKKm) USD Foreign exchange rate guidance
Slide 47: US Mesh litigation – Overview of financial impact
US Mesh litigation – Overview of financial impact P&L Balance Cash flow Assets Actual/Expected cash flow, DKKbn 13/14 14/15 15/16 16/17 17/18 18/19 19/20 Restricted cash, DKKbn 0.5 0.5 EBIT (before special items) 4,147 4,535 4,846 5,024 5,091 5,556 5,854 Special items -1,000 -3,000 - 750 0 0 -400 -
Slide 48: Health reform landscape
Health reform landscape Europe Rest of World • Greece: Reimbursement pressure on all BAs • U.S.: Reimbursement pressure on OC and CC (Managed Care) • Germany: Reimbursement pressure on WC • Brazil: Macroeconomic and political challenges • Netherlands: Reimbursement pressure on OC and CC • Russia: Ma
Slide 49: CARE helps us increase retention and improve product compliance
CARE helps us increase retention and improve product compliance We co-develop CARE content with CARE is a personal and “high- Global program with shared local clinicians touch” program infrastructure Advisors available on phone Clinically validated content and call protocol - ERP Website with reliab
Slide 50: DtC marketing program
With our DtC marketing program we reach into the community We operate in numerous channels to expose our service …and with the reach we get several benefits and product offering… Expose innovative products Ensure product accessibility Ensure successful experience Page 50
Slide 51: Distribution and reimbursement of our products
The generic model for distribution and reimbursement of our products Prescription & Insurance Product Payer Reimbursement price Distribution Prescription & Insurance Consumer $ Product . Page 51
Slide 52: Interventional Urology's revenue is balanced
Interventional Urology’s revenue is balanced geographically and across the four business areas Interventional Urology at a Glance ~15% market share in global market of DKK 12-13bn market FY 18/19 growing 3-5% annually 11% Coloplast position, FY 18/19 Endourology Men’s Health Women’s Health Bladder H
Slide 53: Select products
Coloplast Interventional Urology is split into four business areas MEN’S WOMEN’S SPECIALTY ENDOUROLOGY HEALTH HEALTH INTERVENTIONS • Erectile Dysfunction • Stress Urinary Incontinence • Stone Management • Bladder Drainage • Male Incontinence (SUI) • Transurethral • Benign prostatic hyperplasia • Tes
Slide 54: Strong presence in our categories but room to capture share
We have a strong presence in our categories but there is room to capture market share Coloplast Share Competitive Share Men’s Health Women’s Health Endourology1 Bladder Health & Surgery1 <5% 30-35% <5% 35-45% 35-45% 10-15% 15-20% Inflatable Penile Male Stress urinary Pelvic organ Prosthesis (IPP) in
Slide 55: Global Advanced Wound Care market
The global Advanced Wound Care market remains large and growing despite a challenging 19/20 The Advanced Wound Care market remains a significant Silicone Foams and Gelling Fibers are the two biggest value pool and is expected to grow despite the pandemic categories and grow faster than the market Ma
Slide 56: The Wound & Skin Care 2025 strategic plan
The Wound & Skin Care 2025 strategic plan Scale our China business Build on positive momentum in EU by strengthening our commercial in silicone and 3DFit Technology and foundation and accelerate in silicone increase share of voice in selected with 3DFit Technology markets Scale our US business in Ac
Slide 57: Innovation is the biggest growth driver in US Ostomy Care
In US Ostomy Care, innovation is the biggest growth driver and we continue to win across patient pathway We have gained significant share over the last Innovation is a key driver, and we will continue to expand our offering years of high-quality products Bags & Plates acute share SenSura® Mio portfo
Slide 58: Investing up to DKK 250m in sustainable environmental development
We are investing up to DKK 250m1 over the next 5 years to support sustainable environmental development Key Sustainability Targets 2025 Scope 1+2 emissions2 Renewable energy Company cars are Reduce business travel3 electrical Reducing emissions 100% 67% -10% while being a growth company 50% 6% 0% 1%
Slide 59: Reducing emissions while growing 7-9% organically
We are committed to reducing emissions while growing 7-9% organically 2025 target 2025 target 0 100% 7% Emissions from scope Renewable energy 6% 1 +2 2025 target 13% Our greenhouse 2025 target 5% gas emissions in • Reductions dependent on how much the Limit on goods 19/20* impact of product and pack
Slide 60: Commitment to responsible operations
We continue our strong commitment to responsible operations Key Sustainability Targets 2025 100% 2.0 Responsible White-collars trained in operations Code of Conduct Loss-time injury rate* is our core values 30% 75% Female representation of teams (Director and above) at VP+ levels meet diverse team t
Slide 61: Introducing Ostomy Care
Introducing Ostomy Care Disease areas Key products Distribution of • Colorectal cancer (est. 45%) revenues* • Bladder cancer (est. 10%) • Diverticulitis (est. 15%) Urostomy • Inflammatory bowel disease (est. 10%) Ileostomy • Other (est. 20%) Colostomy Customer groups • Nurses, mainly stoma care nurs
Slide 62: Introducing Ostomy Care Supporting Products
Introducing Ostomy Care Supporting Products Market fundamentals Key products Brava® is a range of ostomy supporting products • Market size of DKK ~3bn designed to reduce leakage or care for skin, to make • Market growth of 6-8% • Market share 35-40% Brava® Protective Seal our end-users feel secure.
Slide 63: Introducing Continence Care
Introducing Continence Care Disease areas Key products Distribution of • Spinal Cord Injured, SCI revenues • Spina Bifida, SB • Multiple Sclerosis, MS Intermittent catheters • Benign prostatic hyperplasia, BPH & prostatectomy patients Urine bags • Elderly Male ext. catheters Bowel management CC Othe
Slide 64: Introducing Bowel Management
Introducing Bowel Management Disease areas Market dynamics Faecal incontinence + Growing awareness (management products only) + Huge underpenetrated and Customer groups unserved population • Spinal Cord Injured, SCI + New devices addressing the many • Spina Bifida, SB unmet needs • Multiple Sclerosi
Slide 65: Introducing Interventional Urology
Introducing Interventional Urology Treatment (surgical) of urological disorders Disease areas Key products Distribution of revenues • Urinary incontinence • Pelvic organ prolapse Men’s health • Erectile dysfunction Women’s health • Enlarged prostate • Kidney and urinary stones Single use devices Cus
Slide 66: Introducing Wound Care
Introducing Wound Care Disease areas Key products Distribution of revenues Chronic wounds (WSC) • Leg ulcers Biatain® range • Diabetic foot ulcers Comfeel® range • Pressure ulcers Skin Care Wound Care other Customer groups Contract manufacturing & call points Hospitals Biatain® Silicone, incl. Sizes
Slide 67: Introducing Skin Care
Introducing Skin Care Disease areas Key products Product mix • Moisture associated skin damage Protectants & Antifungals • Incontinence Cleansing/Bathing • Skin folds & obesity Moisturizers • Prevention of skin impairments Textile SC Other Customer groups & call points Sween® EasiCleanse Bath® Hospi
Slide 68: Product market for US Skin Care
Product market for US Skin Care Market drivers/limiters US Skin Care at a glance + Aging and obese population • US market size estimated at DKK + CMS Value Based Purchasing 4-5bn with 2-4% growth + Increased focus on prevention + Increased importance of utilization • Market share: 10-15% management
Slide 69: The Coloplast organisation
The Coloplast organisation Coloplast Group Chronic Care Strategic Business Units Chronic Care Strategic Business Units Ostomy Care Continence Care Wound & Skin Care Interventional Urology R&D Marketing Sales R&D Marketing Marketing Operations Sales Regions Global Operations Global Business Support F
Slide 70: Coloplast Executive Leadership Team
Coloplast Executive Leadership Team Kristian Villumsen President, CEO • Born 1970 • With Coloplast since 2008 Nicolai Buhl Andersen Anders Lonning-Skovgaard Paul Marcun Camilla G. Møhl Allan Rasmussen EVP, Innovation EVP, CFO EVP, Growth SVP, People & Culture EVP, Operations • Born 1969 • Born 1972
Slide 71: Income statement
Income statement DKKm FY 2018/19 FY 2019/20 Change Revenue 17,939 18,544 3% Gross profit 12,153 12,612 4% SG&A costs -5,963 -6,079 2% R&D costs -692 -708 2% Other operating income/expenses 58 29 -50% Operating profit (EBIT) before special items 5,556 5,854 5% Special items -400 - nm Operating profit
Slide 72: Balance sheet
Balance sheet DKKm 30 Sep 2019 30 Sep 2020 Change Balance, total 12,732 13,499 6% Assets Non-current assets 6,373 7,010 10% Current assets 6,359 6,489 2% of which: Inventories 1,933 2,227 15% Trade receivables 3,153 2,934 -7% Restricted cash 13 - nm Marketable securities, cash, and cash equivalents
Slide 73: Cash flow
Cash flow DKKm FY 2018/19 FY 2019/20 Change EBIT 5,156 5,854 14% Depreciation and amortisation 651 851 31% Change in working capital -291 -352 21% Net interest payments -187 -182 -3% Paid tax -1,185 -1,277 8% Adjustment for other non-cash operating items 213 -135 nm Cash flow from operations 4,357 4
Slide 74: Manufacturing setup
Manufacturing setup Production by country (Volume)¹ 4% Hungary 11% 0% 2% Mørdrup Tatabánya China Minneapolis Sarlat Nyirbátor US/France Mankato Denmark Zhuhai Costa Rica Costa Rica 83% COGS by cost type² 10% 18% Salary - Direct 12% Salary - Indirect 8% Materials (RM &SFG) Innovation & Specialised Pr
Slide 75: Production sites
Production sites Hungary China Tatabánya Zhuhai • Ostomy care products • Continence care products • Adhesives • Ostomy care products • Continence care products • Machine building • Interventional Urology products • Number of employees in production: ~1,000 • Number of employees in production: ~1,950
Slide 76: Production sites
Production sites Denmark US Mørdrup Minneapolis • Pilot development work Ostomy care, • Interventional Urology products Continence care and Wound care • Number of employees in production: ~100 • Adhesives production • Number of employees in production: ~150 France Mankato • Skin care products Sarlat
Slide 77: Coloplast Sponsored Level 1 ADR programme
Coloplast Sponsored Level 1 ADR programme Coloplast Sponsored ADR Programme Benefits of a Coloplast ADR programme to US Investors: • Coloplast has established a sponsored ADR programme in the US, as a Symbol CLPBY service to US investors by offering an alternative way to trade Coloplast shares, whil
Slide 78: Contact Investor Relations
Contact Investor Relations Holtedam 1 DK-3050 Humlebæk Denmark Ellen Bjurgert Rasmus Sørensen Hannah Katrine Larsen Sophia Mastrell Vice President, Investor Relations Senior Manager, Investor Relations Investor Relations Coordinator & PA Student Assistant, Investor Relations Tel. direct: +45 4911 33
Slide 79: Our mission, values and vision
Our mission Making life easier for peoplé with intimate healthcare needs Our values Closeness... to better understand. - Passion... to make a difference Respect and responsibility... to 0 guide | US: Our vision Setting the global standard for listening and responding: Coloplast Group - Ostomy Care /